Regeneron Pharmaceuticals
Clinical trials sponsored by Regeneron Pharmaceuticals, explained in plain language.
-
Can antibodies and vaccine work together? new study investigates
⭐️ VACCINE ⭐️ CompletedThis study looked at whether giving Regeneron's antibody treatment (casirivimab+imdevimab) along with the Moderna COVID-19 vaccine changes how well the vaccine works. About 295 healthy adults took part. Researchers measured immune responses and checked safety to see if the timing…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:55 UTC
-
New immunotherapy shows promise against lung cancer in major trial
Disease control CompletedThis phase 3 trial tested the immunotherapy drug cemiplimab against standard platinum-based chemotherapy in 712 patients with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. The study aimed to see if cemiplimab improves overall survival and delays ca…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could an asthma drug tame this brutal blistering disease?
Disease control CompletedThis study tested whether dupilumab, a drug already used for asthma and eczema, can help people with bullous pemphigoid, a painful blistering skin condition. 106 adults received either dupilumab or a placebo, plus standard steroid treatment. The main goal was to see if more peopl…
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for rare fat disorder
Disease control CompletedThis study tested an experimental drug called REGN4461 in 16 people with generalized lipodystrophy, a rare condition where the body can't store fat properly, leading to severe metabolic problems. The drug aims to improve blood sugar and triglyceride levels. Participants received …
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New syringe could simplify High-Dose eye treatment
Disease control CompletedThis study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Eczema drug dupilumab shows promise in skin of color patients
Disease control CompletedThis study tested the drug dupilumab (Dupixent) in 124 adolescents and adults with darker skin tones who have moderate-to-severe eczema. Participants received injections every two weeks for 24 weeks. The goal was to see if the drug safely improves skin symptoms and quality of lif…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental antibody aims to stabilize blood pressure in sepsis patients
Disease control CompletedThis study tested an experimental drug called REGN7544 in 76 adults hospitalized with sepsis and low blood pressure. The drug is an antibody designed to help raise blood pressure and reduce the need for standard medications. Researchers measured safety, blood pressure changes, an…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy plus chemotherapy shows promise in advanced lung cancer trial
Disease control CompletedThis phase 3 study tested whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 789 participants and compared different drug combinations. The main goal was to see if the com…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug shows promise
Disease control CompletedThis study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug targets harmful blood fats in early trial
Disease control CompletedThis early-stage study tested an experimental drug called ALN-APOC3 in 32 adults with dyslipidemia (abnormal blood fat levels). The main goal was to check safety and how the drug affects fat levels in the blood. Participants were otherwise healthy and either not on statins or on …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New blood clot drug tested in humans for first time
Disease control CompletedThis early-stage trial tested the safety of a new drug called REGN9533 in 72 healthy adults. REGN9533 is a monoclonal antibody that blocks factor XII, a protein involved in blood clotting. The goal was to see if it is safe and how the body processes it, before testing it in peopl…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New shot shrinks skin cancer before surgery, early study shows promise
Disease control CompletedThis early study tested a drug called cemiplimab, which helps the immune system attack cancer cells. The drug was injected directly into skin tumors (squamous cell or basal cell carcinoma) for 3 to 12 weeks before planned surgery. The main goal was to check safety and find the ri…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Shrinking skin cancer before surgery: new drug shows promise
Disease control CompletedThis study tested giving the drug cemiplimab before surgery to people with advanced skin cancer (stage II to IV). The goal was to see if the drug could shrink or eliminate the tumor before the operation. 79 adults took part. The main focus was on how many patients had no cancer c…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for kids with swallowing trouble: drug targets esophageal inflammation
Disease control CompletedThis study tested dupilumab (Dupixent) in 102 children with active eosinophilic esophagitis, a condition where white blood cells build up in the esophagus, causing pain and swallowing problems. The drug aims to reduce inflammation and improve tissue health. Results will show if d…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Real-World study shows cemiplimab effective for advanced skin cancer
Disease control CompletedThis study tracked 287 people with advanced skin cancer (squamous cell or basal cell) to see how well the drug cemiplimab works outside of a clinical trial. Researchers measured tumor shrinkage, survival, and side effects. The goal was to understand real-world effectiveness and s…
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody combo for COVID-19 passes early safety check
Disease control CompletedThis early-stage study tested whether a combination of two antibodies (casirivimab and imdevimab) is safe and tolerable in healthy adults. Forty-five volunteers received the antibodies either as a shot under the skin or through an IV. The main goal was to check for side effects, …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo therapy shows promise for Hard-to-Treat cervical cancer
Disease control CompletedThis phase 2 study tested a combination of the immunotherapy drug cemiplimab and an HPV16-targeting vaccine (ISA101b) in 113 adults with recurrent or metastatic HPV16-positive cervical cancer that had progressed after first-line chemotherapy. The goal was to see if the combinatio…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 15:18 UTC
-
New shot may prevent dangerous clots after knee surgery
Prevention CompletedThis study tested an experimental drug called REGN7508 in 179 adults having knee replacement surgery. The goal was to see if it could prevent blood clots in the legs or lungs better than standard care. Researchers also monitored side effects and how the drug moved through the bod…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 12:38 UTC
-
New antibody drugs aim to stop Catheter-Related clots
Prevention CompletedThis study tested two experimental drugs, REGN9933 and REGN7508, to see if they can prevent venous thromboembolism (blood clots) in adults who need a PICC line for at least 14 days. The drugs are monoclonal antibodies that target a clotting factor. 195 participants received a sin…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
New drug could soothe cat allergy eyes
Symptom relief CompletedThis study tested two experimental drugs, REGN1908 and REGN1909, mixed together to reduce eye allergy signs and symptoms in people with cat allergies. The goal was to see how safe and effective the drug is compared to a placebo. The study included 64 participants with a history o…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New drug cocktail aims to stop itchy eyes from birch pollen
Symptom relief CompletedThis study tested two experimental drugs, REGN5713 and REGN5715, given together to reduce eye allergy symptoms caused by birch pollen. Fifty-four adults with a history of moderate to severe birch pollen allergy received the drug combo or a placebo. The main goal was to see if the…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Asthma drug DUPIXENT under the microscope in Real-World registry
Knowledge-focused CompletedThis completed registry followed 718 asthma patients who were starting treatment with DUPIXENT as part of their normal care. Researchers collected information on patient backgrounds, how the drug was used, its long-term effectiveness, and safety in everyday settings. The goal was…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Dupilumab in pregnancy: no major safety signals found
Knowledge-focused CompletedThis study looked at whether the drug dupilumab, used for eczema or asthma, is safe during pregnancy. Researchers compared 581 pregnant women who took dupilumab with those who did not. They tracked birth defects, miscarriages, and infant health up to one year old to see if the dr…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Massive eye drug study reveals rare inflammation risk
Knowledge-focused CompletedThis study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Massive Real-World study investigates rare eye inflammation after common injection
Knowledge-focused CompletedThis completed study analyzed data from nearly 290,000 patients who received aflibercept (Eylea) injections for various retinal diseases. The goal was to estimate how often retinal vasculitis (inflammation of blood vessels in the eye) occurs in real-world clinical practice. Resea…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC